Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates

 
• By Mandy Jackson
Signpost outside is showing Phase 1 and Phase 2
Neurimmune is transitioning from a Phase I to a Phase II company • Source: Shutterstock

More from Strategy

More from Business